Fibroblasts from the growing margin of keloid scars produce higher levels of collagen i and III compared with intralesional and extralesional sites: Clinical implications for lesional site-directed therapy

British Journal of Dermatology

Volumn 164, Issue 1, 2011, Pages 83-96

  Syed, F ^a   Ahmadi, E ^a   Iqbal, S A ^a   Singh, S ^a   McGrouther, D A ^a,b   Bayat, A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; EOSIN; HEMATOXYLIN; MESSENGER RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KELOID; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY; SKIN FIBROBLAST; TISSUE SECTION; WESTERN BLOTTING;

EID: 78650496794     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10048.x     Document Type: Article

References (63)

1. Cosman B, Crikelair GF, Ju DMC, et al. The surgical treatment of keloids. Plast Reconstr Surg 1961; 27: 335-43.
2. Butler PD, Wang Z, Ly DP, et al. Unfolded protein response regulation in keloid cells. J Surg Res 2009; [Epub ahead of print].
3. Calderon M, Lawrence WT, Banes AJ,. Increased proliferation in keloid fibroblasts wounded in vitro. J Surg 1996; 61: 343-51. (Pubitemid 26087681)
4. Butler PD, Ly DP, Longaker MT, Yang GP,. Use of organotypic coculture to study keloid biology. Am J Surg 2008; 195: 144-8.
5. Ketchum LD,. Hypertrophic scars and keloids. Clin Plast Surg 1977; 4: 301-10.
6. Oluwasanmi JO,. Keloids in the African. Clin Plast Surg 1974; 1: 179-95.
7. Tuan TL, Nichter LS,. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998; 4: 19-24.
8. Yoshimoto H, Ishihara H, Ohtsuru A, et al. Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol 1999; 154: 883-9. (Pubitemid 29122607)
9. Ishihara H, Yoshimoto H, Fujioka M, et al. Keloid fibroblasts resist ceramide-induced apoptosis by overexpression of insulin-like growth factor I receptor. J Invest Dermatol 2000; 115: 1065-71. (Pubitemid 32037452)
10. Ladin DA, Hou Z, Patel D, et al. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen 1998; 6: 28-37. (Pubitemid 128656988)
11. Saed GM, Ladin D, Olson J, et al. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol 1998; 134: 963-7. (Pubitemid 28385318)
12. Sayah DN, Soo C, Shaw WW, et al. Down regulation of apoptosis-related genes in keloid tissues. J Surg Res 1999; 87: 209-16. (Pubitemid 30000588)
13. Chodon T, Sugihara T, Igawa HH, et al. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol 2000; 157: 1661-9.
14. Shih B, Bayat A,. Genetics of keloid scarring. Arch Dermatol Res 2010; 302: 319-39.
15. Bolognia JL, Jorizzo JL, Rapini RP,. Dermatology, 2nd edn, Vol. 2. St Louis: Mosby, 2007; 1867.
16. Bock O, Schmid-Ott G, Malewski P, Mrowietz U,. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297: 433-8.
17. Berman B, Flores F,. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997; 37: 755-7. (Pubitemid 27500320)
18. Griffith BH,. The treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg 1966; 38: 202-8.
19. Griffith BH, Monroe CW, McKinney P,. A follow-up study on the treatment of keloids with triamcinolone acetonide. Plast Reconstr Surg 1970; 46: 145-50.
20. Tang YW,. Intra- and postoperative steroid injections for keloids and hypertrophic scars. Br J Plast Surg 1992; 45: 371-3.
21. Alster TS, Tanzi EL,. Hypertrophic scars and keloids. Etiology and management. Am J Clin Dermatol 2003; 4: 235-43. (Pubitemid 36506429)
22. Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T,. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg 2003; 111: 547-55. (Pubitemid 36182286)
23. Studdiford J, Stonehouse A, Altshuler M, Rinzler E,. The management of keloids: hands-on versus hands-off. J Am Board Fam 2008; 21: 149-52. (Pubitemid 351468509)
24. Al-Attar A, Mess S, Thomassen JM, et al. Keloid pathogenesis and treatment. Plast Reconstr Surg 2006; 117: 286-300. (Pubitemid 44391579)
25. Leventhal D, Furr M, Reiter D,. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 2006; 8: 362-8. (Pubitemid 44862494)
26. Lahiri A, Tsiliboti D, Gaze NR,. Experience with difficult keloids. Br J Plast Surg 2001; 54: 633-5. (Pubitemid 32982638)
27. Lee JH, Kim SE, Lee AY,. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol 2008; 47: 183-6.
28. O'Brien L, Pandit A,. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2006; 25: CD003826.
29. Stahl S, Barnea Y, Weiss J, et al. Treatment of earlobe keloids by extralesional excision combined with preoperative and postoperative 'sandwich' radiotherapy. Plast Reconstr Surg 2010; 125: 135-41.
30. Shridharani SM, Magarakis M, Manson PN, et al. The emerging role of antineoplastic agents in the treatment of keloids and hypertrophic scars: a review. Ann Plast Surg 2010; 64: 355-61.
31. Norris JE,. Superficial X-ray therapy in keloid management: a retrospective study of 24 cases and literature review. Plast Reconstr Surg 1995; 95: 1051-5.
32. Seifert O, Mrowietz U,. Keloid scarring: bench and bedside. Arch Dermatol Res 2009; 301: 259-72.
33. Wynn TA,. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007; 117: 524-9.
34. Urioste SS, Arndt KA, Dover JS,. Keloids and hypertrophic scars: review and treatment strategies. Semin Cutan Med Surg 1999; 18: 159-71. (Pubitemid 29262972)
35. Zhang GY, Yi CG, Li X, et al. Troglitazone suppresses transforming growth factor-β1-induced collagen type I expression in keloid fibroblasts. Br J Dermatol 2009; 160: 762-70.
36. Uitto J, Perejda AJ, Abergel RP, et al. Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. Proc Natl Acad Sci USA 1985; 82: 5935-9. (Pubitemid 16218877)
37. Ala-Kokko L, Rintala A, Savolainen ER,. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures. J Invest Dermatol 1987; 89: 238-44. (Pubitemid 17126576)
38. Zhang LQ, Laato M, Muona P, et al. Normal and hypertrophic scars: quantification and localization of messenger RNAs for type I, III, and VI collagens. Br J Dermatol 1994; 130: 453-9. (Pubitemid 24204663)
39. Zhang LQ, Laato M, Muona P, et al. A fibroblast cell line cultured from a hypertrophic scar displays selective downregulation of collagen gene expression: barely detectable messenger RNA levels of the pro alpha 1(III) chain of type III collagen. Arch Dermatol Res 1995; 287: 534-8.
40. Podobed OV, Prozorovskii NN, Kozlov EA, et al. Comparative study of collagen in hypertrophic and keloid scars. Vopr Med Khim 1996; 42: 240-5.
41. Seifert O, Bayat A, Geffers R, et al. Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair Regen 2008; 16: 254-65. (Pubitemid 351342120)
42. Shih B, McGrouther DA, Bayat A,. Identification of novel keloid biomarkers through profiling of tissue biopsies versus cell cultures in keloid margin specimens compared to adjacent normal skin. Eplasty 2010; 10: e24.
43. Naitoh M, Hosokawa N, Kubota H, et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun 2001; 280: 1316-22. (Pubitemid 32917787)
44. Peltonen J, Hsiao LL, Jaakkola S, et al. Activation of collagen gene expression in keloids: co-localization of type I and VI collagen and transforming growth factor-β1 mRNA. J Invest Dermatol 1991; 97: 240-8.
45. Tan KT, Shah N, Pritchard SA, et al. The influence of surgical excision margins on keloid prognosis. Ann Plast Surg 2010; 64: 55-8.
46. Astrid H, Alla S, Raimund WK, et al. Cytokine mRNA and protein expression in primary-culture and repeated-passage synovial fibroblasts from patients with rheumatoid arthritis. Arthritis Res 2002; 4: 117-25. (Pubitemid 34257345)
47. Yuan H, Kaneko T, Matsuo M,. Increased susceptibility of late passage human diploid fibroblasts to oxidative stress. Exp Gerontol 1996; 31: 465-74. (Pubitemid 26234902)
48. Theodore KC,. Eleftherios PD. Immunoassay configurations. In: Immunoassay (, Diamandis EP, Christopoulos TK, eds). San Diego: Academic Press, 1996; 227-36.
49. Akemi K, Yoshiaki H, Kazuya M, et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293: F956-60.
50. Tansey WP,. Freeze-thaw lysis for extraction of proteins from mammalian cells. Cold Spring Harb Protoc 2006; doi:.
51. Herovici C,. A polychrome stain for differentiating precollagen from collagen. Stain Technol 1963; 38: 204-5.
52. Lillie RD, Tracy RE, Pizzolato P, et al. Differential staining of collagen types in paraffin sections: a color change in degraded forms. Virchows Arch 1980; 386: 153-9. (Pubitemid 10095815)
53. Levame M, Meyer F,. The picropolychrome of Herovici: application in the identification of collagen types I and III. Pathol Biol 1986; 35: 1183-8.
54. Salimi-Bejestani MR, McGarry JW, Felstead S, et al. Development of an antibody-detection ELISA for Fasciola hepatica and its evaluation against a commercially available test. Res Vet Sci 2005; 78: 177-81. (Pubitemid 39618912)
55. SEA) α thalassaemia deletion. J Clin Pathol 2009; 62: 147-51.
56. Cosmo Bio Ltd. Code: ACB-EC1-E105-EX. Human Collagen Type-1 ELISA. Tokyo: Cosmo Bio Ltd.
57. Verhaegen PD, van Zuijlen PP, Pennings NM, et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. Wound Repair Regen 2009; 17: 649-56.
58. Diegelmann RF, Bryant CP, Cohen IK,. Tissue alphaglobulins in keloid formation. Plast Reconstr Surg 1977; 59: 418-23.
59. Lim IJ, Phan TT, Bay BH, et al. Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloidlike manner. Am J Physiol Cell Physiol 2002; 283: C212-22.
60. Fusenig NE,. Epithelial-mesenchymal interactions regulate keratinocyte growth and differentiation in-vitro. In: The Keratinocyte Handbook (, Leigh I, Lane B, Watt F, eds). Cambridge: Cambridge University Press, 1994; 71-94.
61. Maas-Szabowski N, Shimotoyodome A, Fusenig NE,. Keratinocyte growth regulation in fibroblast co-cultures via a double paracrine mechanism. J Cell Sci 1999; 112: 1843-53. (Pubitemid 29338810)
62. Mackenzie IC,. Epithelial-mesenchymal interactions in the development and maintenance of epithelial tissues. In: The Keratinocyte Handbook (, Leigh I, Lane B, Watt F, eds). Cambridge: Cambridge University Press, 1994; 243-57.
63. Dalkowski A, Fimmel S, Beutler C, Zouboulis CC,. Cryotherapy modifies synthetic activity and differentiation of keloidal fibroblasts in vitro. Exp Dermatol 2003; 12: 673-81. (Pubitemid 37270730)